NCT05623839View on ClinicalTrials.gov

A Study of LY3305677 in Participants With Obesity Or Overweight

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
OverweightObesity
Interventions
DRUG

LY3305677

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (3)

78209

ICON Early Phase Services, San Antonio

84124

ICON Early Phase Services Lenexa Center, Salt Lake City

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY